High Dose Ifosfamide, Carboplatin and Etoposide With Amifostine Chemoprotection

Study start date: July 1, 1998

Eligibility Criteria: Histologically documented malignancy Metastatic or locally unresectable malignancy Patient may be responding to therapy Responding Stage IIIC/IV or recurrent/refractory ovarian carcinoma (ineligible for other bone marrow or stem cell transplant protocols) Relapsed germ cell carcinomas Relapsed lymphomas (ineligible for other BMT or SCT protocols SCLC in PR or CR Sarcomas in or near complete remission after induction chemotherapy Stage IIIB NSCLC responding to chemotherapy Responsive bladder, head and neck carcinoma, or carcinoma of unknown primary Other tumors without curative or first line therapy (not eligible for phase II or III studies) Aged 18 to 55 Physiologic years -- Performance status: PS 0-1 Prior Treatment > 1 week since surgery or RT > 3 weeks since prior CT Informed Consent Required initial laboratory data: White Cell Count Life ≥ 3000/ul Platelet Count ≥ 100,000/ul Creatinine ≤ 1.5 x normal Bilirubin ≤ 1.5 x normal No current metastases BM Asp & Bx Brain CAT Creatinine Clearance ≥ 60 cc/min SGOT < 2.5 x normal No other serious medical or psychiatric illness which would prevent informed consent or general anesthesia Uncontrolled or severe cardiovascular disease including recent (< 6 months) myocardial infarction, or congestive heart failure Active uncontrolled bacterial, viral, or fungal infection; or an active duodenal ulcer; until these conditions are corrected or controlled Pregnancy Unable to stop taking antihypertensive medication 24 hours prior to administration of Ethyol